Compare HNVR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | PLX |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 182.9M |
| IPO Year | 2022 | 1996 |
| Metric | HNVR | PLX |
|---|---|---|
| Price | $24.04 | $2.60 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.33 | N/A |
| AVG Volume (30 Days) | 24.2K | ★ 846.1K |
| Earning Date | 10-29-2026 | 08-12-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.80 | 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.16 | ★ $9.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.91 | $1.65 |
| 52 Week High | $27.94 | $3.19 |
| Indicator | HNVR | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 44.37 |
| Support Level | $22.27 | $2.59 |
| Resistance Level | $24.38 | $2.75 |
| Average True Range (ATR) | 0.95 | 0.10 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 9.45 | 7.58 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.